Review
Oncology
Logan Roof, Emrullah Yilmaz
Summary: The incidence of HPV-related oropharyngeal squamous cell carcinoma (OPSCC) has been increasing in recent years. Immunotherapy with immune checkpoint inhibitors is being used in the treatment of these patients. Understanding the role of HPV in the tumor immune microenvironment is crucial for the design of immunotherapy clinical trials. HPV has also become a potential therapeutic target, with vaccines and T-cell therapies being developed for the treatment of OPSCC. Studying the combination of HPV targeting and immune checkpoint inhibitors is an area of ongoing research.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Immunology
Mohamed S. Hussein, Qi Li, Rui Mao, Yibing Peng, Yukai He
Summary: Overexpression of c-Jun in TCR-engineered T cells can enhance their expansion, function, and persistence in hepatocellular carcinoma, leading to improved anti-tumor efficacy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Florian Maerkl, Mohamed-Reda Benmebarek, Julius Keyl, Bruno L. Cadilha, Martina Geiger, Clara Karches, Hannah Obeck, Melanie Schwerdtfeger, Stefanos Michaelides, Daria Briukhovetska, Sophia Stock, Jakob Jobst, Philipp Jie Mueller, Lina Majed, Matthias Seifert, Anna-Kristina Kluever, Theo Lorenzini, Ruth Gruenmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Michael von Bergwelt-Baildon, Simon Rothenfusser, Mitchell P. Levesque, Markus Vincent Heppt, Stefan Endres, Christian Klein, Sebastian Kobold
Summary: Melanoma is an immune sensitive disease, and immune check point blockade has shown activity. However, TIL therapy after ICB failure has shown promising efficacy, indicating the potential of cellular therapies. To overcome limitations of TIL treatment, a controlled adoptive cell therapy approach using synthetic agonistic receptors and bispecific antibodies targeting melanoma-associated antigens is proposed.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Philippe Rochigneux, Brice Chanez, Bernadette De Rauglaudre, Emmanuel Mitry, Christian Chabannon, Marine Gilabert
Summary: The mortality of hepatocellular carcinoma (HCC) is rapidly increasing worldwide, and immunotherapy involving engineered T cells has shown promising results in clinical trials for combating liver cancer.
Article
Oncology
Sandhya Sharma, Mae Woods, Naren U. Mehta, Tim Sauer, Kathan S. Parikh, Michael Schmuck-Henneresse, Huimin Zhang, Birju Mehta, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney
Summary: This study found that depleting naive T cells before extracting antigen-specific T cells from patients can enhance their expansion, antigen specificity, and therapeutic potency. By using CD45RA-depleted PBMCs, EBV-specific T cells were successfully generated and applied in clinical trials for lymphoma and viral infections.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Lauren C. Cutmore, John F. Marshall
Summary: CAR T cells are a type of immunotherapy that has revolutionised the treatment of haematological malignancies by genetically modifying a patient's own cells to target and kill cancer cells. However, obstacles such as the individual production of CAR T cells result in variability in the product, longer wait times for treatment, and higher costs. Novel approaches utilizing allogeneic cells, known as off the shelf CAR T cells, have emerged to overcome these challenges.
Review
Immunology
Paul Shafer, Lauren M. Kelly, Valentina Hoyos
Summary: This article presents a review of the use of engineered T cells for cancer therapy. The mechanisms of T cell antigen recognition and signal transduction mediated through CARs and TCRs are discussed, along with the current classes of cancer antigens recognized by TCR T therapies and pre-clinical strategies for TCR discovery and enhancement. The current landscape of clinical trials for TCR T therapy is also reviewed, providing insights into the development of future engineered TCR approaches.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Brigitte Dreno, Amir Khammari, Agnes Fortun, Virginie Vignard, Soraya Saiagh, Tiffany Beauvais, Nicolas Jouand, Sylvain Bercegay, Sylvain Simon, Francois Lang, Nathalie Labarriere
Summary: The study demonstrated the feasibility and safety of using Melan-A and MELOE-1 specific T cells for ACT in metastatic melanoma patients, but the clinical efficacy can be further enhanced by selecting highly reactive T cells based on PD-1 and TIGIT co-expression and combining with ICI such as anti-PD-1.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Immunology
Suzanne Quinn, Natasha Lenart, Victoria Dronzek, Gina M. Scurti, Nasheed M. Hossain, Michael Nishimura
Summary: Immunotherapy is an effective treatment for cancer, but it only works for a small percentage of patients. Adoptive cell transfer (ACT) is a facet of immunotherapy that involves transferring T cells targeting tumor cells to the patient. The main challenges in ACT are improving clinical responses and reducing adverse events. Current research focuses on identifying novel tumor-targeting T cell receptors, improving safety and efficacy, and combining ACT with other immunotherapies.
Review
Immunology
Claudia Giannotta, Federica Autino, Massimo Massaia
Summary: In recent years, the tumor microenvironment (TME) has become a promising target for cancer therapeutic interventions. The TME consists of cancer cells, immune suppressor cells, and immune effector cells, which interact with each other and are influenced by the tumor stroma. The composition and characteristics of the TME can vary depending on the type of cancer. Increasing evidence suggests that unconventional T cells, such as natural killer T cells, mucosal-associated invariant T cells, and γ/δ T cells, play important roles in the protumor or antitumor TME commitment in solid tumors and blood cancers. This review will focus on γ/δ T cells, specifically V?9Vd2 T cells, and discuss their peculiarities, advantages, and disadvantages as potential targets for therapeutic interventions in blood cancers.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Mikiya Tsunoda, Hiroyasu Aoki, Haruka Shimizu, Shigeyuki Shichino, Kouji Matsushima, Satoshi Ueha
Summary: Temporal analysis of T cell receptor (TCR) repertoire is important for monitoring changes in antigen-specific T cells in cancer patients. However, lack of experimental models for temporal analysis within a homogeneous population limits understanding of the relationship between TCR repertoire changes and antitumor responses. Bilateral tumor model showed highly similar T-cell clones in bilateral tumors and different patterns in draining lymph nodes, suggesting independent induction of tumor-reactive T cell clones in each lymph node.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Yi-Chiu Kuo, Cheng-Fu Kuo, Kurt Jenkins, Alfur Fu-Hsin Hung, Wen-Chung Chang, Miso Park, Brenda Aguilar, Renate Starr, Jonathan Hibbard, Christine Brown, John C. Williams
Summary: The use of universal CAR T cells shows promise in improving the efficacy of cancer treatment and has broad potential applications.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Pouya Safarzadeh Kozani, Mohammad Ali Shokrgozar, Mehdi Evazalipour, Mehryar Habibi Roudkenar
Summary: This study successfully knocked out the endogenous TCR in Jurkat cells using CRISPR/Cas9 and expressed specific exogenous TCRs using lentiviral vectors. Functional assays demonstrated that engineered cells expressed CD69 when co-cultured with peptide-pulsed T2 cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Immunology
Yifan Xu, Jin Jiang, Yutong Wang, Wei Wang, Haokun Li, Wenyu Lai, Zhipeng Zhou, Wei Zhu, Zheng Xiang, Zhiming Wang, Zhe Zhu, Lingfeng Yu, Xiaolan Huang, Hua Zheng, Sha Wu
Summary: Gynecologic malignancies are leading causes of death among women worldwide, and adoptive T cell therapy using engineered T cells has shown promising efficacy in treating tumors. Ongoing research is driving the application of this therapy in the treatment of gynecologic malignancies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Qian Zhu, Guoliang Qiao, Lefu Huang, Chang Xu, Deliang Guo, Shuo Wang, Jing Zhao, Yuguang Song, Bing Liu, Zheng Chen, Zhiyong Yang, Yufeng Yuan
Summary: This study aimed to investigate the relationship between the restoration of CD8(+)PD-1(+) T cells through adoptive T-cell therapy (ACT) and the prognosis and therapeutic response to anti-PD-1 in patients with advanced pancreatic cancer (APC). The results showed that the CD8(+)PD-1(+) T-cell level was related to the expression of PD-L1. Restoring CD8(+)PD-1(+) T cells through ACT significantly improved the prognosis and facilitated the response to anti-PD-1 in APC patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Thomas E. Schaus, Sungwook Woo, Feng Xuan, Xi Chen, Peng Yin
NATURE COMMUNICATIONS
(2017)
Article
Biochemical Research Methods
Na Li, Jessica N. Ebright, Gwendolyn M. Stovall, Xi Chen, Hong Hanh Nguyen, Amrita Singh, Angel Syrett, Andrew D. Ellington
JOURNAL OF PROTEOME RESEARCH
(2009)
Article
Chemistry, Multidisciplinary
Xi Chen
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2012)
Article
Chemistry, Multidisciplinary
Bingling Li, Yu Jiang, Xi Chen, Andrew D. Ellington
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2012)
Article
Chemistry, Multidisciplinary
Steven M. Chirieleison, Peter B. Allen, Zack B. Simpson, Andrew D. Ellington, Xi Chen
Article
Biochemistry & Molecular Biology
Bingling Li, Andrew D. Ellington, Xi Chen
NUCLEIC ACIDS RESEARCH
(2011)
Article
Multidisciplinary Sciences
Xi Chen, Neima Briggs, Jeremy R. McLain, Andrew D. Ellington
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2013)
Article
Biochemistry & Molecular Biology
Xi Chen, Lisa Denison, Matthew Levy, Andrew D. Ellington
Article
Biochemical Research Methods
Xi Chen, Andrew D. Ellington
PLOS COMPUTATIONAL BIOLOGY
(2009)
Article
Biotechnology & Applied Microbiology
Austin N. Southard-Smith, Alan J. Simmons, Bob Chen, Angela L. Jones, Marisol A. Ramirez Solano, Paige N. Vega, Cherie' R. Scurrah, Yue Zhao, Michael J. Brenan, Jiekun Xuan, Martha J. Shrubsole, Ely B. Porter, Xi Chen, Colin J. H. Brenan, Qi Liu, Lauren N. M. Quigley, Ken S. Lau
Article
Oncology
Teng Wei, Matthias Leisegang, Ming Xia, Kazuma Kiyotani, Ning Li, Chenquan Zeng, Chunyan Deng, Jinxing Jiang, Makiko Harada, Nishant Agrawal, Liangping Li, Hui Qi, Yusuke Nakamura, Lili Ren
Summary: This study explores the use of TCR-engineered T cells in adoptive cell therapy for treating relapsed and metastatic cancers, by utilizing blood-derived T cells and HLA-matched APCs to overcome challenges in isolating PBMCs from advanced-stage cancer patients. The established protocol provides flexibility in identifying neoantigen-specific TCRs when patient PBMCs and tumor material are not available.
Review
Biochemistry & Molecular Biology
Xi Chen, Na Li, Andrew D. Ellington
CHEMISTRY & BIODIVERSITY
(2007)